Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.54 |
| ▸ | MMP13 | P45452 | 3/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.52 |
| ▸ | PRKACA | P17612 | 2/20 | 0.51 |
| ▸ | PRKX | P51817 | 2/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.51 |
| ▸ | GRK5 | P34947 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407266 | 0.90 | MAPK14 (0.76) | MAPK14CYP2C9ROCK1ROCK2MMP13 | |
| SCHEMBL13009619 | 0.86 | MAPK14 (0.55) | MAPK14CYP2C9ROCK1ROCK2MMP13 | |
| SCHEMBL3409350 | 0.85 | MAPK14 (0.56) | MAPK14CYP2C9ROCK1ROCK2MMP13 | |
| SCHEMBL3404864 | 0.85 | MAPK14 (0.87) | MAPK14CYP2C9MAPK11 | |
| SCHEMBL3410654 | 0.84 | MAPK14 (0.62) | MAPK14CYP2C9ROCK1ROCK2MAPK11 | |
| SCHEMBL3405640 | 0.83 | MAPK14 (0.68) | MAPK14CYP2C9MAPK11 | |
| SCHEMBL3405290 | 0.81 | MAPK14 (0.51) | MAPK14CYP2C9ROCK1ROCK2MMP13 | |
| SCHEMBL12013950 | 0.81 | ROCK2 (0.51) | MAPK14CYP2C9ROCK1ROCK2MMP13 | |
| SCHEMBL3408198 | 0.80 | ROCK2 (0.50) | MAPK14CYP2C9ROCK1ROCK2MMP13 | |
| SCHEMBL3093483 | 0.79 | MAPK14 (0.68) | MAPK14CYP2C9ROCK1ROCK2MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575204-B2 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575204-B2 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575204-B2 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2258687-B1 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8252818-B2 | Nicotinamide derivatives useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252818-B2 | Nicotinamide derivatives useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252818-B2 | Nicotinamide derivatives useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2258687-A1 | Nicotinamide derivates useful as P38 inhibitors | Glaxosmithkline LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258687-A1 | Nicotinamide derivates useful as P38 inhibitors | Glaxosmithkline LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100215661-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-08-26 | — | — | US | disclosed |
| EP-1864975-A2 | Novel compounds | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1864975-A2 | Novel compounds | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1474395-B1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1474395-B1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060276516-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060264479-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-11-23 | — | — | US | disclosed |
| US-7125898-B2 | Nicotinamide derivatives useful as p38 inhibitors. | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC | 2005-08-11 | — | — | US | disclosed |
| EP-1474395-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003068747-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264479-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | MAPK1, MAPK7, MAPK6 | MAPK14 10/4885CYP2C9 2948/4885ROCK1 881/4885 |
| US-20100215661-A1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | MAPK1, MAPK7, MAPK4 | MAPK14 12/4885CYP2C9 2539/4885ROCK1 820/4885 |
| US-20060276516-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | MAPK1, MAPK7, MAPK6 | MAPK14 10/4885CYP2C9 2948/4885ROCK1 881/4885 |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | MAPK1, MAPK7, MAPK6 | MAPK14 10/4885CYP2C9 2948/4885ROCK1 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.